QUAD Investment Management
Investments
48Portfolio Exits
7About QUAD Investment Management
QUAD Investment Management is an independent investment manager overseeing approximately US$2.0 billion in equity assets (as of November 2017). Its clients range from institutional clients such as pension funds, endowments and family offices to individual parents and their children.
Latest QUAD Investment Management News
Apr 26, 2023
New investors K2 HealthVentures, Korea Investment Partners, Korea Investment & Securities Asia Ltd and Korea Investment & Securities US Inc, and existing investors including co-founder PureTech Health, Revelation Partners, QUAD Investment Management, Seventure Partners, Hambro Perks and Pfizer Inc also participated. Vedanta Biosciences intends to use the funds to advance a pivotal Phase III trial of its lead candidate, VE303, to prevent recurrent clostridioides difficile infection (CDI). VE303 is an orally administered, “rationally designed”, defined bacterial consortium candidate. It comprises eight types of clonal human commensal bacteria strains chosen to offer colonisation resistance to C difficile. The funds will also be used to support a proof-of-concept Phase II trial of VE202 to treat ulcerative colitis. Vedanta Biosciences co-founder and CEO Bernat Olle said: “We are grateful to have the support of our new and existing investors, who share our vision of pioneering microbiome therapeutics based on defined bacterial consortia to transform the lives of patients with serious diseases. “Our Phase II clinical data and this new funding enable us to continue advancing the microbiome field beyond products made from faecal donations and towards pharmaceutical-grade, defined medicines.” Share this article
QUAD Investment Management Investments
48 Investments
QUAD Investment Management has made 48 investments. Their latest investment was in Novorex as part of their Series B on November 11, 2023.
QUAD Investment Management Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
11/21/2023 | Series B | Novorex | $8.86M | Yes | 3 | |
10/26/2023 | Series B | Medipixel | $12.52M | No | 1 | |
9/26/2023 | Series B | Neocannbio | $7.4M | Yes | 2 | |
5/15/2023 | Series A | |||||
4/25/2023 | Series E |
Date | 11/21/2023 | 10/26/2023 | 9/26/2023 | 5/15/2023 | 4/25/2023 |
|---|---|---|---|---|---|
Round | Series B | Series B | Series B | Series A | Series E |
Company | Novorex | Medipixel | Neocannbio | ||
Amount | $8.86M | $12.52M | $7.4M | ||
New? | Yes | No | Yes | ||
Co-Investors | |||||
Sources | 3 | 1 | 2 |
QUAD Investment Management Portfolio Exits
7 Portfolio Exits
QUAD Investment Management has 7 portfolio exits. Their latest portfolio exit was Curiox on August 03, 2023.
QUAD Investment Management Team
1 Team Member
QUAD Investment Management has 1 team member, including current Managing Director, Youngtae Hong.
Name | Work History | Title | Status |
|---|---|---|---|
Youngtae Hong | Managing Director | Current |
Name | Youngtae Hong |
|---|---|
Work History | |
Title | Managing Director |
Status | Current |
Loading...